How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,338 results for

Risperidone

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Two cases of life‐threatening arrhythmia induced by risperidone: evaluation of risperidone and 9‐hydroxy‐risperidone concentrations (PubMed)

Two cases of life‐threatening arrhythmia induced by risperidone: evaluation of risperidone and 9‐hydroxy‐risperidone concentrations Case 1: A 20-year-old woman suffering a suspected overdose was transported to the hospital. She presented bradycardia with wide QRS waves and QT prolongation, followed by cardiac arrest. Extracorporeal cardiopulmonary resuscitation was implemented, improving circulation. Risperidone and 9OH-RIS levels were 9.6 ng/mL and 127.6 ng/mL, respectively. Case 2: A 54 (...) -year-old woman was hospitalized for femoral fracture and underwent surgery. Her electrocardiogram showed bradycardia and complete AV block. Risperidone and 9OH-RIS levels were 3.2 ng/mL and 61.4 ng/mL, respectively.In both cases, only serum concentration of 90H-RIS were elevated.Arrhythmia related to risperidone has proven rare but sometimes fatal. Serum concentrations of risperidone and the metabolite 9-hydroxy-risperidone (9OH-RIS) during these events are seldom documented. As 9OH-RIS shows

Full Text available with Trip Pro

2017 Acute medicine & surgery

2. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). (PubMed)

Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). Aggressive, agitated or violent behaviour due to psychosis constitutes an emergency psychiatric treatment where fast-acting interventions are required. Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation.To examine whether oral risperidone alone is an effective treatment for psychosis-induced aggression or agitation.We searched the Cochrane (...) of risperidone and other drugs, combinations of drugs or placebo for people exhibiting aggression or agitation (or both) thought to be due to psychosis.We independently inspected all citations from searches, identified relevant abstracts, and independently extracted data from all included studies. For binary data we calculated risk ratio (RR) and for continuous data we calculated mean difference (MD), all with 95% confidence intervals (CI) and used a fixed-effect model. We assessed risk of bias

Full Text available with Trip Pro

2018 Cochrane

3. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. (PubMed)

Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substance use disorders (dual diagnosis). Dual diagnosis can have an adverse effect on treatment and prognosis of SMI.To evaluate the effects of risperidone compared to treatment with other antipsychotics (first-generation and other second-generation antipsychotics) used (...) in people with serious mental illness and co-occurring substance misuse.On 6 January 2016 and 9 October 2017, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (including trial registers).We selected randomised trials of risperidone versus any other antipsychotic in people with SMI and substance abuse (dual diagnosis). We included trials meeting our inclusion criteria and reporting useable data. We excluded trials that either did not meet our inclusion criteria or met our

Full Text available with Trip Pro

2018 Cochrane

4. Risperidone

Risperidone Top results for risperidone - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for risperidone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

5. Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study (PubMed)

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study Risperidone is the first new generation antipsychotic drug to become available as a long-acting injection (LAI). The purpose of this study was to evaluate the effects of switching from oral risperidone to risperidone LAI (RLAI) on cognitive function in stable schizophrenia patients compared with the effects of continuing (...) oral risperidone.Sixteen stable patients who had received risperidone monotherapy for at least 3 months were enrolled (the RLAI group). Before and 24 weeks after switching to RLAI, the Japanese-language version of the Brief Assessment of Cognition in Schizophrenia (BACS-J) and the Positive and Negative Syndrome Scale (PANSS) were administered. To exclude the possibility of learning effects on the BACS-J results, 14 patients with stable schizophrenia who continued oral risperidone treatment were

Full Text available with Trip Pro

2018 Frontiers in Psychiatry Controlled trial quality: uncertain

6. Risperidone (depot) for schizophrenia. (PubMed)

Risperidone (depot) for schizophrenia. Risperidone is the first new generation antipsychotic drug made available in a long-acting injection formulation.To examine the effects of depot risperidone for treatment of schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medication.To critically appraise and summarise current evidence on the resource use, cost and cost-effectiveness of risperidone (depot) for schizophrenia.We searched the Cochrane (...) Schizophrenia Group's Register (December 2002, 2012, and October 28, 2015). We also checked the references of all included studies, and contacted industry and authors of included studies.Randomised clinical trials comparing depot risperidone with other treatments for people with schizophrenia and/or schizophrenia-like psychoses.Two review authors independently selected trials, assessed trial quality and extracted data. For dichotomous data, we calculated the risk ratio (RR), with 95% confidence interval (CI

Full Text available with Trip Pro

2016 Cochrane

7. WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. (PubMed)

WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics. The efficacy of risperidone has already been compared to conventional drugs, but it remains unclear how risperidone compares with other (...) atypical antipsychotic drugs such as clozapine.To determine the effects of risperidone compared with other atypical antipsychotic drugs for schizophrenia.Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 2000), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999), MEDLINE (1966-1999), LILACS (1982-1999), PSYNDEX (1977-1999) and PsycLIT (1974-1999) were undertaken. In addition, pharmaceutical databases on the Dialog Corporation Datastar

Full Text available with Trip Pro

2016 Cochrane

8. The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function. (PubMed)

The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function. To evaluate the effect of maintenance modified electroconvulsive therapy (MECT) on schizophrenic patients.From June 2012 to June 2014, 62 patients with schizophrenia, who had recovered from a successful course of acute MECT, were recruited. Thirty-one patients received maintenance MECT and risperidone (...) , as the experimental group. Another 31 patients were enrolled in the control group, and received risperidone only. The effects on cognitive functions, clinical symptoms and relapse rate were determined.Patients in the experimental group had a lower relapse rate and longer relapse-free survival time than the controls. Relative to the baseline evaluation, patients showed statistically significant improvement in verbal memory and visual memory. At the final assessment, the scores of verbal and visual memory were

Full Text available with Trip Pro

2017 Arquivos de neuro-psiquiatria Controlled trial quality: uncertain

9. Risperidone in Elderly Schizophrenic Patients: An Open-Label Trial. (PubMed)

Risperidone in Elderly Schizophrenic Patients: An Open-Label Trial. The authors assessed the safety and efficacy of risperidone in a group of elderly patients with chronic schizophrenia and behavioral disturbances (N = 10). There were no clinically significant changes on physical examination. Also, schizophrenic symptoms and cognitive performance improved during risperidone administration. Patients showed a sufficient improvement in both areas to warrant a larger, double-blind study assessing (...) the effects of risperidone on cognitive and psychiatric symptoms in elderly psychotic patients.Copyright © 1996 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

2019 The American Journal of Geriatric Psychiatry Controlled trial quality: uncertain

10. The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice. (PubMed)

The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice. Atypical antipsychotic medications such as risperidone are widely prescribed for diverse psychiatric indications including schizophrenia, bipolar disorder and depression. These medications have complex pharmacology and are associated with significant endocrine and metabolic side effects. This class of medications also carries FDA black box warnings due to increased risk of death in elderly patients (...) . Clinical reports indicate that patients treated with these medications are more susceptible to infections; however, the underlying mechanisms/pharmacology are unclear. We have previously reported that risperidone and it's active metabolite distributes to the bone marrow in clinically relevant concentrations in preclinical species, leading us to hypothesize that the hematopoietic system may be impacted by these medications. To test this hypothesis, using proteomic and cytokine array technology, we

Full Text available with Trip Pro

2019 PLoS ONE

11. Safety of risperidone in schizophrenia and bipolar disorder diagnosed patients - a systematic review and meta-analysis

Safety of risperidone in schizophrenia and bipolar disorder diagnosed patients - a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

12. Efficacy and side effects of risperidone use in autism spectrum disorder: a systematic review and meta-analysis

Efficacy and side effects of risperidone use in autism spectrum disorder: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

13. Clozapine versus risperidone for people with schizophrenia [Cochrane protocol]

Clozapine versus risperidone for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

14. CYP2D6 genotype and pharmacokinetics of oral and long-acting injectable risperidone: a systematic review and meta-analysis

CYP2D6 genotype and pharmacokinetics of oral and long-acting injectable risperidone: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

15. Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia

Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia HAS - Medical, Economic and Public Health Assessment Division 1/16 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 February 2014 RISPERDAL 1 mg, scored film-coated tablet B/60 (CIP: 34009 338 948 7 0) RISPERDAL 2 mg, scored film-coated tablet B/60 (CIP (...) for injection in prefilled syringe B/1 (CIP: 34009 362 494 2 4) HAS - Medical, Economic and Public Health Assessment Division 2/16 Applicant: JANSSEN-CILAG INN Risperidone ATC code N05AX08 (Antipsychotics) Reason for the review Renewal of inclusion Extension of indication in the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer's dementia unresponsive to non pharmacological approaches and when there is a risk of harm to self or others. Lists

2014 Haute Autorite de sante

16. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

17. In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. (PubMed)

In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. 28320006 2017 12 08 2018 12 02 1539-3704 166 6 2017 03 21 Annals of internal medicine Ann. Intern. Med. In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. JC32 10.7326/ACPJC-2017-166-6-032 Lee Justin J Holbrook Anne A McMaster UniversityHamilton, Ontario, Canada. eng Journal Article Comment United States Ann Intern Med 0372351 0003-4819 (...) 0 Antipsychotic Agents J6292F8L3D Haloperidol L6UH7ZF8HC Risperidone AIM IM JAMA Intern Med. 2017 Jan 1;177(1):34-42 27918778 Antipsychotic Agents Delirium Double-Blind Method Haloperidol Humans Palliative Care Risperidone 2017 3 21 6 0 2017 3 21 6 0 2017 12 9 6 0 ppublish 28320006 2612421 10.7326/ACPJC-2017-166-6-032

2017 Annals of Internal Medicine Controlled trial quality: uncertain

18. CYP2D6 genotype and adverse events to risperidone in children and adolescents. (PubMed)

CYP2D6 genotype and adverse events to risperidone in children and adolescents. There are few and conflicting data on the role of cytochrome P450 2D6 (CYP2D6) polymorphisms in relation to risperidone adverse events (AEs) in children. This study assessed the association between CYP2D6 metabolizer status and risk for risperidone AEs in children.Children ≤18 years with at least 4 weeks of risperidone exposure were identified using BioVU, a de-identified DNA biobank linked to electronic health (...) , and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P = 0.03).Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs. Pre-prescription genotyping could identify this high-risk subset for an alternate therapy, risperidone dose reduction, and/or increased monitoring for AEs.

2019 Pediatric Research

19. Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study. (PubMed)

Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study. Many people with intellectual disabilities use risperidone long term for the management of challenging behaviours, despite its limited proof of effectiveness and its clear association with adverse events. Therefore, this study aimed to investigate the effectiveness of ongoing treatment (...) with risperidone in reducing challenging behaviours versus controlled discontinuation on behaviour and health parameters.This was a placebo-controlled, double-blind, randomised discontinuation trial of risperidone. In the discontinuation group, risperidone was gradually replaced by a placebo over 14 weeks, while the control group maintained their existing dosage. Eight weeks after discontinuation, behaviour (as measured by the 'Aberrant Behavior Checklist') and health parameters (dyskinesia, akathisia

2019 Journal of intellectual disability research : JIDR Controlled trial quality: uncertain

20. Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. (PubMed)

Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. Risperidone, an atypical antipsychotic medication, is recommended as a first line treatment for acute mania in patients with bipolar disorder I (BD I). It is unknown if continuing treatment with risperidone adjunct to lithium or valproate after remission of the manic episode offers additional benefit in prevention of mood episode relapse.A post-hoc subgroup analysis was conducted (...) using data from a 52-week, double-blind, placebo controlled trial involving 93 patients treated with oral risperidone adjunct to mood stabilizer, randomized to arms discontinuing risperidone at entry ("0-week arm"), 24 weeks after entry ("24-week arm") or continuing risperidone ("52-week arm"). Time to any episode, manic episode, and depressive episode was compared between arms using Cox regression models.Time to any mood episode was longer in the 24-week arm versus the 0-week arm (HR: 0.57, 95% CI

2019 Journal of Affective Disorders Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>